Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors

Cell

Volumn 167, Issue 2, 2016, Pages 419-432.e16

  Roybal, Kole T ^a,b,c   Williams, Jasper Z ^a,b,c   Morsut, Leonardo ^a,b,c   Rupp, Levi J ^a,b,c   Kolinko, Isabel ^a,b,c   Choe, Joseph H ^a,b,c   Walker, Whitney J ^a,b,c   McNally, Krista A ^a,b,c   Lim, Wendell A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Center for Systems and Synthetic Biology   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

cancer; CARs; cellular engineering; immunotherapy; synthetic biology; synthetic Notch; T cells

Indexed keywords

NOTCH RECEPTOR; SYNTHETIC NOTCH RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; ANTIBODY; ARTIFICIAL RECEPTOR; CYTOKINE;

ARTICLE; CELL ENGINEERING; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROCEDURES; TH1 CELL; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL ENGINEERING; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ARTIFICIAL; RECEPTORS, NOTCH; TH1 CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; TUMOR MICROENVIRONMENT;

EID: 84990855364     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.09.011     Document Type: Article

References (63)

1. Akira, S., Takeda, K., Toll-like receptor signalling. Nat. Rev. Immunol. 4 (2004), 499–511.
2. Amarnath, S., Mangus, C.W., Wang, J.C.M., Wei, F., He, A., Kapoor, V., Foley, J.E., Massey, P.R., Felizardo, T.C., Riley, J.L., et al. The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci. Transl. Med., 3, 2011, 111ra120.
3. Anderson, R., Macdonald, I., Corbett, T., Hacking, G., Lowdell, M.W., Prentice, H.G., Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum. Gene Ther. 8 (1997), 1125–1135.
4. Barrett, D.M., Singh, N., Porter, D.L., Grupp, S.A., June, C.H., Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65 (2014), 333–347.
5. Barrett, D.M., Teachey, D.T., Grupp, S.A., Toxicity management for patients receiving novel T-cell engaging therapies. Curr. Opin. Pediatr. 26 (2014), 43–49.
6. Bray, S.J., Notch signalling: a simple pathway becomes complex. Nat. Rev. Mol. Cell Biol. 7 (2006), 678–689.
7. Brentjens, R.J., Davila, M.L., Rivière, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
8. Chen, L., Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol. 4 (2004), 336–347.
9. Chovatiya, R., Medzhitov, R., Stress, inflammation, and defense of homeostasis. Mol. Cell 54 (2014), 281–288.
10. Davila, M.L., Rivière, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med., 6, 2014, 224ra25.
11. Dotti, G., Gottschalk, S., Savoldo, B., Brenner, M.K., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol. Rev. 257 (2014), 107–126.
12. Dranoff, G., Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4 (2004), 11–22.
13. Fischbach, M.A., Bluestone, J.A., Lim, W.A., Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med., 5, 2013, 179ps7.
14. Fridy, P.C., Li, Y., Keegan, S., Thompson, M.K., Nudelman, I., Scheid, J.F., Oeffinger, M., Nussenzweig, M.C., Fenyö, D., Chait, B.T., Rout, M.P., A robust pipeline for rapid production of versatile nanobody repertoires. Nat. Methods 11 (2014), 1253–1260.
15. Gajewski, T.F., Schreiber, H., Fu, Y.-X., Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14 (2013), 1014–1022.
16. Gill, S., June, C.H., Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies. Immunol. Rev. 263 (2015), 68–89.
17. Gordon, W.R., Vardar-Ulu, D., Histen, G., Sanchez-Irizarry, C., Aster, J.C., Blacklow, S.C., Structural basis for autoinhibition of Notch. Nat. Struct. Mol. Biol. 14 (2007), 295–300.
18. Gordon, W.R., Zimmerman, B., He, L., Miles, L.J., Huang, J., Tiyanont, K., McArthur, D.G., Aster, J.C., Perrimon, N., Loparo, J.J., Blacklow, S.C., Mechanical allostery: evidence for a force requirement in the proteolytic activation of Notch. Dev. Cell 33 (2015), 729–736.
19. Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 (2013), 1509–1518.
20. Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat. Immunol. 16 (2015), 343–353.
21. Johnstone, R.W., Frew, A.J., Smyth, M.J., The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008), 782–798.
22. June, C.H., Blazar, B.R., Riley, J.L., Engineering lymphocyte subsets: tools, trials and tribulations. Nat. Rev. Immunol. 9 (2009), 704–716.
23. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
24. Kara, E.E., Comerford, I., Fenix, K.A., Bastow, C.R., Gregor, C.E., McKenzie, D.R., McColl, S.R., Tailored immune responses: novel effector helper T cell subsets in protective immunity. PLoS Pathog., 10, 2014, e1003905.
25. Kim, K., Fisher, M.J., Xu, S.Q., el-Deiry, W.S., Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6 (2000), 335–346.
26. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M., Sadelain, M., Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31 (2013), 71–75.
27. Lacy, M.Q., Jacobus, S., Blood, E.A., Kay, N.E., Rajkumar, S.V., Greipp, P.R., Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk. Res. 33 (2009), 1485–1489.
28. Lamers, C.H.J., Sleijfer, S., Vulto, A.G., Kruit, W.H.J., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., Oosterwijk, E., Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24 (2006), e20–e22.
29. Lämmermann, T., Sixt, M., The microanatomy of T-cell responses. Immunol. Rev. 221 (2008), 26–43.
30. Lecourtois, M., Schweisguth, F., Indirect evidence for Delta-dependent intracellular processing of notch in Drosophila embryos. Curr. Biol. 8 (1998), 771–774.
31. Leigh, N.D., Bian, G., Ding, X., Liu, H., Aygun-Sunar, S., Burdelya, L.G., Gudkov, A.V., Cao, X., A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS ONE, 9, 2014, e85587.
32. Lemke, J., von Karstedt, S., Zinngrebe, J., Walczak, H., Getting TRAIL back on track for cancer therapy. Cell Death Differ. 21 (2014), 1350–1364.
33. Lim, W.A., Designing customized cell signalling circuits. Nat. Rev. Mol. Cell Biol. 11 (2010), 393–403.
34. Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E.C., Cogdill, A.P., Li, N., Ramones, M., Granda, B., et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75 (2015), 3596–3607.
35. Magee, M.S., Snook, A.E., Challenges to chimeric antigen receptor (CAR)-T cell therapy for cancer. Discov. Med. 18 (2014), 265–271.
36. Maus, M.V., Fraietta, J.A., Levine, B.L., Kalos, M., Zhao, Y., June, C.H., Adoptive immunotherapy for cancer or viruses. Annu. Rev. Immunol. 32 (2014), 189–225.
37. Miller, J.F.A.P., Sadelain, M., The journey from discoveries in fundamental immunology to cancer immunotherapy. Cancer Cell 27 (2015), 439–449.
38. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
39. Morsut, L., Roybal, K.T., Xiong, X., Gordley, R.M., Coyle, S.M., Thomson, M., Lim, W.A., Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 164 (2016), 780–791.
40. Mueller, S.N., Gebhardt, T., Carbone, F.R., Heath, W.R., Memory T cell subsets, migration patterns, and tissue residence. Annu. Rev. Immunol. 31 (2013), 137–161.
41. Mumm, J.S., Schroeter, E.H., Saxena, M.T., Griesemer, A., Tian, X., Pan, D.J., Ray, W.J., Kopan, R., A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol. Cell 5 (2000), 197–206.
42. Nagorsen, D., Kufer, P., Baeuerle, P.A., Bargou, R., Blinatumomab: a historical perspective. Pharmacol. Ther. 136 (2012), 334–342.
43. Nair, P.M., Flores, H., Gogineni, A., Marsters, S., Lawrence, D.A., Kelley, R.F., Ngu, H., Sagolla, M., Komuves, L., Bourgon, R., et al. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc. Natl. Acad. Sci. USA 112 (2015), 5679–5684.
44. O'Garra, A., Barrat, F.J., Castro, A.G., Vicari, A., Hawrylowicz, C., Strategies for use of IL-10 or its antagonists in human disease. Immunol. Rev. 223 (2008), 114–131.
45. O'Shea, J.J., Paul, W.E., Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327 (2010), 1098–1102.
46. O'Shea, J.J., Ma, A., Lipsky, P., Cytokines and autoimmunity. Nat. Rev. Immunol. 2 (2002), 37–45.
47. Ouyang, W., Rutz, S., Crellin, N.K., Valdez, P.A., Hymowitz, S.G., Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu. Rev. Immunol. 29 (2011), 71–109.
48. Park, S.-J., Kim, M.-J., Kim, H.-B., Sohn, H.-Y., Bae, J.-H., Kang, C.-D., Kim, S.-H., Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells. Exp. Cell Res. 315 (2009), 1809–1818.
49. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
50. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
51. Roybal, K.T., Rupp, L.J., Morsut, L., Walker, W.J., McNally, K.A., Park, J.S., Lim, W.A., Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164 (2016), 770–779.
52. Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., Regulatory T cells and immune tolerance. Cell 133 (2008), 775–787.
53. Selkoe, D., Kopan, R., Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26 (2003), 565–597.
54. Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
55. Smanski, M.J., Bhatia, S., Zhao, D., Park, Y., B A Woodruff, L., Giannoukos, G., Ciulla, D., Busby, M., Calderon, J., Nicol, R., et al. Functional optimization of gene clusters by combinatorial design and assembly. Nat. Biotechnol. 32 (2014), 1241–1249.
56. Stinchcombe, J.C., Griffiths, G.M., Secretory mechanisms in cell-mediated cytotoxicity. Annu. Rev. Cell Dev. Biol. 23 (2007), 495–517.
57. Struhl, G., Adachi, A., Nuclear access and action of notch in vivo. Cell 93 (1998), 649–660.
58. Sundrud, M.S., Grill, S.M., Ni, D., Nagata, K., Alkan, S.S., Subramaniam, A., Unutmaz, D., Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J. Immunol. 171 (2003), 3542–3549.
59. Tang, H., Qiao, J., Fu, Y.-X., Immunotherapy and tumor microenvironment. Cancer Lett. 370 (2016), 85–90.
60. Temizoz, B., Kuroda, E., Ishii, K.J., Vaccine adjuvants as potential cancer immunotherapeutics. Int. Immunol. 28 (2016), 329–338.
61. Walczak, H., Miller, R.E., Ariail, K., Gliniak, B., Griffith, T.S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999), 157–163.
62. Zhao, Y., Wang, Q.J., Yang, S., Kochenderfer, J.N., Zheng, Z., Zhong, X., Sadelain, M., Eshhar, Z., Rosenberg, S.A., Morgan, R.A., A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183 (2009), 5563–5574.
63. Zou, W., Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006), 295–307.